Septerna (SEPN) shares were down sharply premarket Tuesday after the company said it has discontinued a phase 1 clinical trial of SEP-786 for the potential treatment of hypoparathyroidism in healthy volunteers.
The company said the decision follows two unanticipated severe events of elevated unconjugated bilirubin in a portion of the trial, though there were no occurrences of liver injury, cholestasis, or hemolysis among participants and no serious adverse events.
The company said its cash, cash equivalents, and marketable securities totaled $137.5 million as of Sept. 30. Together with $302.6 million in net proceeds from its October IPO, Septerna said it expects its current cash position to support operations into at least H2 2027.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.